"The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.
- Patient Information:
Details with Side Effects
Doses titrated up to 300 mg once daily have been safely administered to patients on dialysis. Overdosage of Sensipar (cinacalcet) may lead to hypocalcemia. In the event of overdosage, patients should be monitored for signs and symptoms of hypocalcemia and appropriate measures taken to correct serum calcium levels [see WARNINGS AND PRECAUTIONS].
Since Sensipar (cinacalcet) is highly protein bound, hemodialysis is not an effective treatment for overdosage of Sensipar (cinacalcet) .
Hypocalcemia: Sensipar (cinacalcet) treatment should not be initiated if serum calcium is less than the lower limit of the normal range [see WARNINGS AND PRECAUTIONS].
Last reviewed on RxList: 4/19/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Sensipar Information
Sensipar - User Reviews
Sensipar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.